Skip to main content
OpenTrials

Clinical trial condition

Peripheral T-cell Lymphoma

Explore clinical trials studying Peripheral T-cell Lymphoma. Study availability and eligibility vary by location and protocol.

100 public trials 16 recruiting studies
Refine in advanced search Browse all conditions

Peripheral T-cell Lymphoma trial results

Completed

Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL

NCT02362997

Conditions
Diffuse Large B Cell Lymphoma, Hemic and Lymphatic Diseases, Hodgkin Disease, +14 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details
Completed

Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma

NCT01846390

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations
  • Tom Baker Cancer Centre Calgary, Alberta, Canada
  • BCCA - Vancouver Cancer Centre Vancouver, British Columbia, Canada
  • Regional Health Authority B, Zone 2 Saint John, New Brunswick, Canada
  • QEII Health Sciences Centre Halifax, Nova Scotia, Canada
View Trial Details
Completed

A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

NCT04569032

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Stanford Cancer Center Stanford, California, United States
  • Stanford Hospital and Clinics, Investigational Drug Services Stanford, California, United States
View all 63 locations
View Trial Details
Completed

AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26)

NCT06511869

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Anhui Provincial Hospital (The First Affiliated Hospital of USTC) Hefei, Anhui, China
  • Peking university Third Hospital Beijing, Beijing Municipality, China
  • The First Affiliated Hospital of Chongqing Medical University Chongqing, Chongqing Municipality, China
  • Guangdong Provincial People's Hospital Guangzhou, Guangdong, China
View all 23 locations
View Trial Details
Completed

A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

NCT03372057

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • University of California - Irvine Irvine, California, United States
  • University of California - Los Angeles Los Angeles, California, United States
  • Emory University Winship Cancer Institute Atlanta, Georgia, United States
View all 36 locations
View Trial Details

Related conditions